Based on our expertise in immunoassays, Cisbio Bioassays developed a Chromogranin A immunoradiometric assay by selecting antibodies targeting the core of the molecule (145-245) relatively unaffected by proteolysis. This antibody choice and the analytical accuracy of the assay mean high analytical and clinical performances in testing for neuroendocrine tumors. Chromogranin A measurements in neuroendocrine tumors are established in the guidelines* as an aid for diagnosis, treatment efficiency and prognostic factors. The CGA-RIACT assay gives numerous analytical and clinical benefits, as shown in references in the literature, and is easy to install and operate in laboratories. *guidelines
- Home
- Products
- In-Vitro Diagnostics
- Oncology
- CgA RIA
Chromogranin A (CGA) immunoradiometric assay kit
Features
- Working range: 0 ? 1200 ng/mL
- Sample: serum or plasma ? 50 ?L
- Analytical sensitivity: 1.5 ng/mL
Applications
- High specificity and sensitivity in neuroendocrine tumors
- Diagnosis and follow-up in neuroendocrine tumors such as pheochromocytoma, gastrinoma, and carcinoid tumors
- Diagnosis and management of Small-Cell lung carcinomas (SCLC)
- Adverse prognostic factor in prostate cancer independent of PSA
- Diagnosis and management of ectopic Cushing’s syndrome
Assay principle
IRMA
Coated tubes
Two monoclonal antibodies are used for a sandwich-type test, and are directed against the central domain of the molecule (145 - 245) which is less sensitive to proteolysis. The first monoclonal antibody is adsorbed onto the tube walls, while the second antibody radiolabelled with iodine-125 is used as the tracer.
*Two-step assay procedure: 18h at RT + 2h at RT / shaking.